Salarius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Decoy Therapeutics

11/05/2023 14:39

* Salarius Pharmaceuticals Inc  SLRX.OQ  reported a
quarterly
adjusted loss of $2.23​​ per share for the quarter ended in
March. The mean expectation of three analysts for the quarter
was for a loss of $2.50 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Salarius Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $2.23​.
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Salarius Pharmaceuticals Inc shares had fallen by 22.5%
this
quarter and lost 3.3% so far this year.
    * The company reported a quarterly loss of $5.34 million.
    * Wall Street's median 12-month price target for Salarius
Pharmaceuticals Inc is $17.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 01:39 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -2.50          -2.23          Beat
 Dec. 31 2022      -2.15          -2.83          Missed
 Sep. 30 2022      -2.55          -2.47          Beat
 Jun. 30 2022      -2.62          -2.25          Beat